Alnylam Pharmaceuticals, Inc. (ALNY)财务
NASDAQ · Healthcare · Biotechnology · 员工2,500人 · CEO Yvonne L. Greenstreet
- 股价
- $165.00 -5.17%
- 市值
- $221亿
- 企业价值
- $216亿
- 最近财报
- Q3 '26 2026-10-29提交
- 下次财报
- 2027-02-11 EPS预期 $1.75
营收(TTM)$50.1亿+56.2% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)19.5%+11.3 百分点 对比去年同期营业利润 $9.78亿
净利润(TTM)$27.2亿+6,153.3% 对比去年同期税后,含营业外收益
自由现金流(TTM)$5.01亿+126.2% 对比去年同期资本支出 $1.5亿
稀释EPS(TTM)$19.80+8,150.0% 对比去年同期最近4个季度之和
净现金$23.3亿+64.2% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $221亿 EV $216亿
- 营收
- $50.1亿 过去12个月
- 营收增速
- +47% FY2026年一致预期
- 净利润率
- 54.3% 净利润 / 营收,TTM
- P/E
- 8.1× 预期 9.3×(FY2026)
- P/S
- 4.4× 股价 / 营收,TTM
- EV / EBITDA
- 17.3× TTM
- 自由现金流
- $5.01亿 过去12个月
- 净利润
- $27.2亿 过去12个月
- 营收预期
- $54.4亿 FY2026年一致预期
- 盈利
- 2027-02-11 营收预期 $15.3亿
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-10-29):营收超预期1.9%,EPS 超预期879.5%营收$14.6亿,预期$14.3亿(+1.9%);EPS $16.26,预期$1.66(+879.5%)。
- 营收增长放缓:同比16.7%Q3 '26营收$14.6亿,此前四个季度的平均值为99.4%。
- 营业利润率19.5%(TTM),较去年同期+11.3 百分点营收增长56.2%,营业利润增长269.3%。
- 税前利润的14.2%被营业外亏损吞噬税前利润$8.56亿,营业利润$9.78亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 资本支出占营收的3.0%(去年为1.4%)最近4个季度投入$1.5亿(同比+236.3%)。自由现金流$5.01亿,相当于净利润的18.4%。
- 稀释股数一年内增加0.5%Q3 '26稀释股数1.38亿,一年前为1.37亿。
- 净现金 $23.3亿现金 + 短期投资 $35.9亿,含租赁债务 $12.6亿;一年前净现金 $14.2亿。
上一季度:Q3 '26
截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q3 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $14.6亿 | $12.5亿 | +16.7% |
| 毛利率 | 75.2% | 84.2% | -9.0 百分点 |
| 营业利润 | $3.46亿 | $3.68亿 | -6.0% |
| 营业利润率 | 23.7% | 29.5% | -5.7 百分点 |
| 净利润 | $21.7亿 | $2.51亿 | +763.2% |
| 稀释EPS | $15.72 | $1.84 | +754.3% |
| 经营现金流 | $3.41亿 | $3.25亿 | +4.9% |
| 资本支出 | $6980万 | $1210万 | +475.1% |
| 自由现金流 | $2.71亿 | $3.13亿 | -13.4% |
| R&D | $4.09亿 | $3.59亿 | +13.9% |
| 股权激励费用 | $7910万 | $1.08亿 | -26.9% |
实际 vs 一致预期
2026-10-29| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $14.6亿 | $14.3亿 | +1.9% |
| EPS(一致预期口径) | $16.26 | $1.66 | +879.5% |
来自2026-10-29发布的Q3 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Product | $12.9亿 | – | 92.2% | – | – | |
| GIVLAARI | $8950万 | – | 6.4% | $4.14亿 | – | |
| ONPATTRO | $1960万 | – | 1.4% | $1.29亿 | – |
按地区划分的营收
占总额比例| 分部 | Q3 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $9.09亿 | – | 80.4% | $35.9亿 | – | |
| Europe | $1.31亿 | – | 11.6% | $5.96亿 | – | |
| Non-US Or Europe | $9100万 | – | 8.1% | $3.56亿 | – |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- $6.5亿
- 资本支出
- -$1.5亿
- 股票回购
- $0
- 股息
- $0
- 收购
- $0
- 债务净发行
- -$5580万
- 股权激励费用
- $3.08亿
- 自由现金流
- $5.01亿
- 股东回报 / FCF
- -0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 8.1× | 166.4× 5年中的1年 | 166.4× – 166.4× |
| EV / EBITDA | 17.3× | 81.9× 5年中的1年 | 81.9× – 81.9× |
| EV / 营收 | 4.3× | 18.6× | 13.3× – 28.3× |
| 股价 / FCF | 44.1× | 341.0× 5年中的2年 | 111.9× – 570.0× |
| 股价 / 净资产 | 6.1× | 182.6× 5年中的3年 | 34.1× – 447.7× |
| FCF收益率 | 2.3% | -1.0% | -3.6% – 0.9% |
| 投入资本回报率 | 15.4% | -10.3% | -27.8% – 13.7% |
| 净资产收益率 | 159.7% | 78.9% | -414.6% – 714.9% |
分析师
一致目标价 $330.54 (+100.3%)
区间 $225.00 – $455.00 · 评级 Buy
强烈买入0
买入38
持有13
卖出1
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $54.4亿 | +46.5% | $17.81 | +664.4% | 9.3× | 14 |
| FY2027 | $66.6亿 | +22.3% | $9.19 | -48.4% | 18.0× | 16 |
| FY2028 | $79亿 | +18.7% | $11.47 | +24.8% | 14.4× | 17 |
| FY2029 | $89.7亿 | +13.4% | $12.92 | +12.7% | 12.8× | 12 |
| FY2030 | $99.8亿 | +11.3% | $15.16 | +17.3% | 10.9× | 7 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Alnylam Pharmaceuticals, Inc.在近期10-Q / 10-K文件中标记的全部197项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $1.35亿 | $1.18亿 | +15.1% | $1.16亿 | $8840万 | +30.9% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $10.8亿 | $9.65亿 | +12.5% | $7.78亿 | $4.05亿 | +91.8% |
| Accrued Liabilities, Current | $12.4亿 | $11.5亿 | +7.2% | $10.8亿 | $7.94亿 | +36.1% |
| Accrued Professional Fees, Current | $3430万2025-12-31 | $2000万 | +71.9% | $3430万 | $2000万 | +71.9% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $3.23亿2025-12-31 | $2.7亿 | +19.4% | $3.23亿 | $2.7亿 | +19.4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$4470万 | -$2180万 | -105.1% | -$2010万 | -$3450万 | +41.8% |
| Additional Paid in Capital, Common Stock | $78.1亿 | $74.1亿 | +5.4% | $75.1亿 | $73.9亿 | +1.7% |
| Advertising Expense | – | – | – | $3600万 | $2970万 | +21.2% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 136万 | 179万 | -24.2% | 336万 | 1140万 | -70.6% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $8020万 | $1.09亿 | -26.6% | $3.53亿 | $2.75亿 | +28.1% |
| Assets | $79.9亿 | $48.5亿 | +64.8% | $49.7亿 | $42.4亿 | +17.1% |
| Assets, Current | $51.1亿 | $39.5亿 | +29.3% | $40.5亿 | $33亿 | +22.9% |
| Assets, Fair Value Disclosure | $20.5亿 | – | – | $14.2亿 | $19.9亿 | -28.8% |
| Capital Expenditures Incurred but Not yet Paid | $520万 | $552万 | -5.9% | $1090万 | $232万 | +369.1% |
| Capitalized Contract Cost, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Cash and Cash Equivalents, at Carrying Value | $17.5亿 | $14.9亿 | +17.7% | $16.6亿 | $9.66亿 | +71.5% |
| Cash and Cash Equivalents, Fair Value Disclosure | $4420万 | $2500万 | +76.7% | $2360万 | $6910万 | -65.8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $17.6亿 | $14.9亿 | +17.6% | $16.6亿 | $9.69亿 | +71.2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $14.9亿2025-09-30 | $11亿 | +35.4% | $8.69亿2022-12-31 | $8.22亿 | +5.6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $4630万 | $3.77亿 | -87.7% | $6.9亿 | $1.54亿 | +348.8% |
| Common Stock, Par or Stated Value Per Share | $0.01 | $0.01 | 0.0% | $0.01 | $0.01 | 0.0% |
| Common Stock, Shares Authorized | 2.5亿 | 2.5亿 | 0.0% | 2.5亿 | 2.5亿 | 0.0% |
| Common Stock, Shares, Issued | 1.34亿 | 1.32亿 | +1.6% | 1.32亿 | 1.29亿 | +2.4% |
| Common Stock, Shares, Outstanding | 1.34亿 | 1.32亿 | +1.6% | 1.32亿 | 1.29亿 | +2.4% |
| Common Stock, Value, Issued | $134万 | $132万 | +1.6% | $132万 | $129万 | +2.4% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $21.5亿 | $3.01亿 | +616.2% | $3.28亿 | -$2.89亿 | +213.4% |
| Contract with Customer, Liability, Current | $1170万 | $254万 | +359.2% | $485万 | $5550万 | -91.3% |
| Contract with Customer, Liability, Revenue Recognized | $400万 | $1250万 | -68.0% | $5380万 | $2.67亿 | -79.8% |
| Convertible Debt, Current | $3.62亿 | – | – | – | – | – |
| Convertible Debt, Noncurrent | $6.51亿 | $10.4亿 | -37.4% | $10.1亿 | $10.2亿 | -1.6% |
| Cost of Goods and Services Sold | $3.62亿 | $1.97亿 | +83.4% | $6.77亿 | $3.07亿 | +120.9% |
| Costs and Expenses | $11.1亿 | $8.81亿 | +26.2% | $32.1亿 | $24.3亿 | +32.5% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $967万 | $594万 | +62.7% |
| Current Income Tax Expense (Benefit) | – | – | – | $1160万 | $754万 | +53.8% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $193万 | $160万 | +20.9% |
| Debt Instrument, Interest Rate, Stated Percentage | 10.0%2025-12-31 | 10.0% | 0.0% | 10.0% | 10.0% | 0.0% |
| Debt Securities, Available-for-sale | $12.6亿2025-09-30 | $16.8亿 | -25.1% | $17.9亿2024-12-31 | $16.5亿 | +8.4% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $346万2025-09-30 | $648万 | -46.6% | $272万2024-12-31 | $303万 | -10.2% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $9.4万2025-09-30 | $14.6万 | -35.6% | $118万2024-12-31 | $148万 | -20.5% |
| Debt Securities, Available-for-sale, Amortized Cost | $12.6亿2025-09-30 | $16.7亿 | -25.0% | $17.9亿2024-12-31 | $16.5亿 | +8.5% |
| Debt Securities, Available-for-sale, Current | $18.3亿 | $12.3亿 | +48.5% | $12.5亿 | $17.2亿 | -27.3% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$220万 | -$1.07亿 | +97.9% |
| Deferred Income Tax Assets, Net | $20.1亿 | $9860万 | +1,936.0% | $1.26亿 | $1.17亿 | +7.8% |
| Deferred Income Tax Expense (Benefit) | -$18.9亿 | $560万 | -33,946.6% | -$220万 | -$1.07亿 | +97.9% |
| Deferred Tax Assets, Deferred Income | $122万2025-12-31 | $1450万 | -91.6% | $122万 | $1450万 | -91.6% |
| Deferred Tax Assets, Derivative Instruments | $02025-12-31 | $1.08亿 | -100.0% | $0 | $1.08亿 | -100.0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $5.94亿2025-12-31 | $6.34亿 | -6.4% | $5.94亿 | $6.34亿 | -6.4% |
| Deferred Tax Assets, Gross | $29.2亿2025-12-31 | $29.7亿 | -1.7% | $29.2亿 | $29.7亿 | -1.7% |
| Deferred Tax Assets, Net | $1.26亿2025-12-31 | $1.17亿 | +7.8% | $1.26亿 | $1.17亿 | +7.8% |
| Deferred Tax Assets, Operating Loss Carryforwards | $9.87亿2025-12-31 | $8.83亿 | +11.8% | $9.87亿 | $8.83亿 | +11.8% |
| Deferred Tax Assets, Other | $9060万2025-12-31 | $8640万 | +4.9% | $9060万 | $8640万 | +4.9% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $4.52亿2025-12-31 | $3.92亿 | +15.5% | $4.52亿 | $3.92亿 | +15.5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $7000万2025-12-31 | $6210万 | +12.7% | $7000万 | $6210万 | +12.7% |
| Deferred Tax Assets, Valuation Allowance | $27.3亿2025-12-31 | $27.9亿 | -2.0% | $27.3亿 | $27.9亿 | -2.0% |
| Deferred Tax Liabilities, Leasing Arrangements | $4180万2025-12-31 | $4120万 | +1.5% | $4180万 | $4120万 | +1.5% |
| Deferred Tax Liabilities, Other Comprehensive Income | $02025-12-31 | $204万 | -100.0% | $0 | $204万 | -100.0% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $1740万2025-12-31 | $1860万 | -6.6% | $1740万 | $1860万 | -6.6% |
| Depreciation | – | – | – | $5480万 | $5510万 | -0.5% |
| Depreciation, Amortization and Accretion, Net | $1450万 | $1380万 | +4.9% | $5570万 | $5670万 | -1.8% |
| Derivative Liability | – | – | – | $4.87亿2024-12-31 | – | – |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
数据截至 2026-11-02